This statistic is based on a survey by Ipsos MORI and shows the difference between the actual percentage of adults aged 20 to 79 years in select countries worldwide who had diabetes and what survey respondents guessed as of 2017. It was found that respondents in the U.S. on average guessed that 34 out of every 100 adults aged 20 to 79 years had diabetes, when in reality the number was 11 out of every 100.

Around ** percent of the global adult population suffered from diabetes in 2024 - by the year 2050 this number is expected to rise to ** percent. Diabetes, or diabetes mellitus, refers to a group of metabolic disorders that result in chronic high blood sugar levels. Diabetes can lead to serious health complications, such as cardiovascular disease, chronic kidney disease, and stroke, and is now among the top ten leading causes of death worldwide. Prevalence Diabetes is a global problem affecting many countries. China currently has the largest number of diabetics worldwide, with some *** million people suffering from the disease. However, the highest prevalence of diabetes is found in Pakistan, followed by the Marshall Islands and Kuwait. Rates of diabetes have increased in many countries in recent years, as have rates of obesity, one of the leading risk factors for the disease. Outlook It is predicted that diabetes will continue to be a problem in the future. Africa is expected to see a *** percent increase in the number of diabetics in the region from 2024 to 2050, while North America and the Caribbean are expected to see an increase of ** percent. In 2050, China is predicted to be the country with the highest number of diabetics worldwide, with the United States accounting for the fourth-highest number.

United States US: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 10.790 % in 2017. United States US: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 10.790 % from Dec 2017 (Median) to 2017, with 1 observations. United States US: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

Timor-Leste TL: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 6.860 % in 2017. Timor-Leste TL: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 6.860 % from Dec 2017 (Median) to 2017, with 1 observations. Timor-Leste TL: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Timor-Leste – Table TL.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

Georgia GE: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 7.110 % in 2017. Georgia GE: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 7.110 % from Dec 2017 (Median) to 2017, with 1 observations. Georgia GE: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Georgia – Table GE.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

Portugal PT: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 9.850 % in 2017. Portugal PT: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 9.850 % from Dec 2017 (Median) to 2017, with 1 observations. Portugal PT: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Portugal – Table PT.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

Sweden SE: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 4.790 % in 2017. Sweden SE: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 4.790 % from Dec 2017 (Median) to 2017, with 1 observations. Sweden SE: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Sweden – Table SE.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

Global Diabetes Care Devices market size was USD 10.26 Billion in 2022 and it is forecasted to reach USD 18.69 Billion by 2030. Diabetes Care Devices Industry's Compound Annual Growth Rate will be 8.76% from 2023 to 2030. Market Dynamics of the Diabetes Care Devices Market

Drivers of the diabetes care device market:

The demand for monitoring and treatment devices is being fuelled by an increase in diabetes prevalence worldwide

Diabetes is becoming more common everywhere, but notably in developing nations like China and India. The prevalence of diabetes is fast increasing, and this is due to a number of causes, including growing urbanisation and an increase in sedentary lifestyle, particularly in developing nations. According to the International Diabetes Federation, there were 425 million adult diabetics worldwide in 2017, and by 2045, that number is expected to reach 630 million. These studies suggest that between 55 and 60 percent of people worldwide have diabetes, with the majority living in China, India, United States, Brazil, and Mexico. Currently, China and India make up about half of the world's diabetic population.

Restraining Factor of the diabetic device care market:

Diabetes care devices tend to be quite expensive and challenging to use

The glucose testing machine is high in price and uncomfortable to use. Diabetes care devices outcomes are not always precise. Additionally, a few things prevent the market from growing. This includes uncomfortable sensor insertions on the body. Additionally, the diabetes care devices cause skin rashes, adhesion problems.

Impact of the COVID-19 pandemic on the Diabetes Care Devices Market: COVID-19 increased the market growth for diabetic care equipment. This is due to the fact that patients with COVID-19 infections were seen to have elevated blood sugar levels. Due to the rising prevalence of diabetes and the expanding market, various firms have introduced innovative, cutting-edge diabetes care devices in the post-pandemic era. One of the biggest global health crises of the twenty-first century is diabetes. This illness, which can cause life-altering problems, is being lived with by an increasing number of people each year. In addition to more than millions adults with impaired glucose tolerance who are at a high risk of getting diabetes in the future, there are an estimated more than half of million adults with diabetes worldwide. With rising obesity rates, shifting food preferences, and an ageing population, diabetes incidence and prevalence are on the rise. Therefore, there is a sizable market potential in the global diabetes care devices & pharmaceuticals market given the enormous numbers of diabetics globally and the enormous financial implications connected with diabetes and linked subsequent health issues.

The top pharmaceutical companies based on global anti-diabetic revenue include big-name pharmaceutical leaders such as Novo Nordisk and Eli Lilly. As of 2017, Novo Nordisk was the top global anti-diabetic revenue generator with over 13.7 billion U.S. dollars in revenue for that year. Novo Nordisk is projected to continue being the top anti-diabetic pharmaceutical company by 2024. They are projected to make about 21 billion U.S. dollars in anti-diabetic pharmaceuticals revenue in the year 2024.

Diabetes treatments and prevalence

Diabetes is a chronic illness caused by the pancreas not producing enough insulin or the body not effectively using insulin. The global prevalence of diabetes in 2017 was about 8.8 percent and that is expected to increase significantly by 2045. Though not all countries are affected equally. Many Pacific Island nations have a significantly higher prevalence of diabetes than the rest of the world. Likewise, not all countries have the same standards of care or costs for care. Norway, Switzerland and the U.S. have the some of the highest costs per person with diabetes as of 2017.

Top diabetes pharmaceuticals

There are many types of treatments for diabetes. As of 2017, Novo Nordisk’s NovoRapid insulin held the highest share among all anti-diabetic products on the market. NovoRapid is primarily used in the treatment of type I diabetes. Other types of insulin are also among the top anti-diabetic products. When based on revenue generated, the top anti-diabetic products included Eli Lilly’s Trulicity and Boehringer Ingelheim’s Jardiance, medications used primarily in the treatment of type 2 diabetes.

BackgroundDiabetes mellitus (DM) is a prominent health concern worldwide, leading to the high incidence of disability and mortality and bringing in heavy healthcare and social burden. Plant-based diets are reported associated with a reduction of DM risk. Plant-based diets are rich in flavonoids, which possess properties such as scavenging free radicals and exerting both anti-inflammatory and antioxidant effects.PurposeHowever, whether dietary flavonoids are associated with the prevalence of DM remains controversial. The potential reasons for contradictory epidemiological outcomes on the association between dietary flavonoids and DM prevalence have not been determined.MethodsTo address these limitations, we employed data from 22,481 participants in the National Health and Nutrition Examination Survey to explore the association between the intake of flavonoids and DM prevalence by weighted Logistic regression and weighted restricted cubic splines.ResultsWe found that the prevalence of DM was inversely associated with the intake of total flavonoids in the second quartile [Odds Ratio (OR) 0.78 95% confidence interval (CI) (0.63, 0.97), p = 0.028], in the third quartile [0.76 (0.60, 0.97), p = 0.031], and in the fourth quartile [0.80 (0.65, 0.97), p = 0.027]. However, the p for trend was not significant [0.94 (0.88, 1.01), p = 0.096]. Moreover, the association between DM prevalence and the intake of total flavonoids was significantly influenced by race (p for interaction = 0.006). In Mexican Americans, there was a significant positive association between DM prevalence and total flavonoid intake within the third quartile [1.04 (1.02, 1.07), p = 0.003]. Total flavan-3-ol and subtotal catechin intake exhibited a non-linear U-shaped association with DM prevalence (p for non-linearity < 0.0001 and p for non-linearity < 0.0001, respectively). Compared to the first quartile of corresponding intakes, consumption within the third quartile of subtotal catechins [0.70 (0.55, 0.89), p = 0.005] and total flavan-3-ols [0.65 (0.50, 0.84), p = 0.002] was associated with a lower prevalence of DM.ConclusionTaken together, our study may provide preliminary research evidence for personalized improvement of dietary habits to reduce the prevalence of diabetes.

Malta MT: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 8.830 % in 2017. Malta MT: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 8.830 % from Dec 2017 (Median) to 2017, with 1 observations. Malta MT: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Malta – Table MT.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

At present, chronic kidney disease is one of the significant problems in Thailand and worldwide. According to the research, the prevalence of chronic kidney disease in 2017 was 697.5 million people across the globe or around 9.1 percent of the world population. The prevalence increased by 29.3 percent from 1990 to 2017. In addition, the study of chronic kidney disease prevalence in Thailand in 10 provinces covering all regions in Thailand found that the prevalence of chronic kidney disease was 17.5 percent, and from the studies with people who have the criteria for chronic kidney disease in every stage, all studies indicate that hyperglycemia and blood pressure affects the development of chronic kidney disease. In a study by the American Association of Diabetes Educators in 2017, diabetes causes chronic kidney disease in 44 percent of all patients with chronic kidney disease. The study of the relationship between overweight and diabetes under the topic of the Mechanism linking diabetes mellitus and obesity 2014 found that increased BMI levels were associated with the development of insulin-resistant diabetes. Of people with type 2 diabetes, 86 percent of these people were associated with being overweight or obese, and, in addition, being overweight and obesity are global health problems. The prevalence of obesity increased dramatically in 2016; there were 1.9 billion adults (people older than 18 years old) worldwide with overweight, of which more than 650 million are obese. The research team sees the importance of chronic kidney disease, which is why the research team decide to study the prevalence and risk factors of chronic kidney disease. In addition, the relationship between overweight and the prevalence of chronic kidney disease patients in Sanam Chai Khet hospital has yet to be studied. For this reason, the research team is interested in studying the relationship between being overweight and the prevalence of chronic kidney disease in Sanam Chai Khet hospital. Therefore, a cross-sectional study investigates chronic kidney disease's prevalence and risk factors in Sanam Chai Khet hospital chronic kidney patients during 2016-2020. The data were retrieved from electronic medical records of the hospital information system. A total of 1263 chronic kidney patients participated in the study; 937 patients were diagnosed with chronic kidney stage 3 or above, a prevalence of 74.19 percent. The risk factors of chronic kidney disease stage 3 or above are patients over 70 years old, with a body mass index greater than 23 kg/m2, diabetes patients, hypertension, and hypertensive crisis.

Journal of Diabetes Research Acceptance Rate - ResearchHelpDesk - Journal of Diabetes Research is a Open Access, peer-reviewed journal that publishes research articles (Orginal Article), clinical studies and review articles related to type one (1) and type two (2) diabetes. The journal welcomes submissions focusing on the etiology, management, pathogenesis, epidemiology and prevention of diabetes, as well as associated complications, such as diabetic neuropathy, retinopathy and nephropathy. Journal of Diabetes Research is archived in Portico, which provides permanent archiving for electronic scholarly journals, as well as via the LOCKSS initiative. It operates a fully open access publishing model which allows open global access to its published content. This model is supported through Article Processing Charges. The most recent Impact Factor for Journal of Diabetes Research is 2.885 according to the 2017 Journal Citation Reports released by Clarivate Analytics in 2018. The journal’s most recent CiteScore is 3.02 according to the CiteScore 2018 metrics released by Scopus.

Diabetes mellitus is a worldwide epidemic disease. Globally, diabetes prevalence is estimated to be 9.3% in 2019 and will rise to 10.2% by 2030 and 10.9% by 2045. Urban population has higher prevalence (10.8%) than rural population (7.2%), and prevalence of high-income countries (10.4%) is more than low-income countries (4.0%). One in two people living with diabetes are undiagnosed.International Diabetes Federation (IDF) has reported that in 2009 it was estimated that 285 million people had diabetes, including both type 1 and type 2 which increased to 366 million in 2011 and 425 million in 2017. The report has projected that number of cases of diabetes will increase to 578 million in 2030.There are three types of diabetes based on insulin production in the body. They are Type 1 (Juvenile diabetes) and Type 2 (Adult diabetes) and gestational diabetes (which occur mostly among pregnant women). Type 1 diabetes accounts for 5% to 10% of the diagnosed cases of whereas, type 2 accounts for 90% to 95% and less than 1% are the rarer types of diabetes. Read More

Jordan JO: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 11.750 % in 2017. Jordan JO: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 11.750 % from Dec 2017 (Median) to 2017, with 1 observations. Jordan JO: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Jordan – Table JO.World Bank.WDI: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

BackgroundType 2 Diabetes Mellitus (T2DM) is reported to affect one in 11 adults worldwide, with over 80% of T2DM patients residing in low-to-middle-income countries. Health systems play an integral role in responding to this increasing global prevalence, and are key to ensuring effective diabetes management. We conducted a systematic review to examine the health system-level factors influencing T2DM awareness, treatment, adherence, and control.Methods and findingsA protocol for this study was published on the PROSPERO international prospective register of systematic reviews (PROSPERO 2016: CRD42016048185). Studies included in this review reported the effects of health systems factors, interventions, policies, or programmes on T2DM control, awareness, treatment, and adherence. The following databases were searched on 22 February 2017: Medline, Embase, Global health, LILACS, Africa-Wide, IMSEAR, IMEMR, and WPRIM. There were no restrictions on date, language, or study designs. Two reviewers independently screened studies for eligibility, extracted the data, and screened for risk of bias. Thereafter, we performed a narrative synthesis. A meta-analysis was not conducted due to methodological heterogeneity across different aspects of included studies. 93 studies were included for qualitative synthesis; 7 were conducted in LMICs. Through this review, we found two key health system barriers to effective T2DM care and management: financial constraints faced by the patient and limited access to health services and medication. We also found three health system factors that facilitate effective T2DM care and management: the use of innovative care models, increased pharmacist involvement in care delivery, and education programmes led by healthcare professionals.ConclusionsThis review points to the importance of reducing, or possibly eliminating, out-of-pocket costs for diabetes medication and self-monitoring supplies. It also points to the potential of adopting more innovative and integrated models of care, and the value of task-sharing of care with pharmacists. More studies which identify the effect of health system arrangements on various outcomes, particularly awareness, are needed.

Incidence, prevalence, DALY and QCI score in 2017, and its percent changes between 1990 and 2017 in 11 causes.

The Diabetes Control and Complications Trial (DCCT) was a multicenter, randomized clinical trial designed to compare intensive with conventional diabetes therapy with regard to their effects on the development and progression of the early vascular and neurologic complications of type 1 insulin-dependent diabetes mellitus. The DCCT study involved 1,441 participants, ages 13 to 39, with type 1 diabetes and either no or minimal background retinopathy. Participants were required to have had diabetes for at least 1 year but no longer than 15 years.

Once enrolled, patients were randomized to receive standard therapy, consisting of not more than two injections of insulin per day, or intensive therapy, consisting of either subcutaneous insulin infusion by pump or at least three subcutaneous injections of insulin daily, targeting near-normal glycemia. Both groups received the same dietary management and education program. Blood glucose and hemoglobin A1c measurements were used as primary indicators of metabolic control. The primary outcome measure was diabetic retinopathy. Other outcome measures included diabetic nephropathy, diabetic neuropathy, and cardiovascular events or their known or putative risk factors. The DCCT study found that intensive therapy showed beneficial effects on retinopathy, nephropathy, and neuropathy when compared with conventional therapy.

Following these findings, the Epidemiology of Diabetes Interventions and Complications (EDIC) study was initiated as follow-up to examine the long-term effects of the original DCCT interventions on diabetic complications such as cardiovascular events and advanced retinal and renal disease. Over 90 percent of participants from the DCCT study were followed by the EDIC study. Similar to the DCCT study, glycosylated hemoglobin values, fasting lipid levels, serum creatinine values, and other risk factors for cardiovascular disease were measured at different intervals for participants. Cardiovascular complications were assessed with standardized means and classified by an independent committee. The EDIC study has found that intensive diabetes therapy reduced risk of cardiovascular disease in patients with type 1 diabetes and that the differences in outcomes between the intensive and conventional therapy groups persist after long-term study.

Data from the DCCT/EDIC study up to June 2017 (the end of EDIC Year 24) are available from the Repository. GWAS data may be requested through dbGAP.

Background Diabetes is a metabolic disorder, characterized by hyperglycemic state of the body. A silent killer, which can take the lives of victims if undiagnosed at the earliest stage. Prediabetes has become an important health concern across countries due to its huge potential for the development of diabetes and other complications. The objectives of this study were to determine the prevalence of prediabetes and diabetes and its associated factors among rural fishing communities in Penang, Malaysia.Methods A cross-sectional study was conducted among fishing communities in Southwest District of Penang, Malaysia from August to November 2017. Blood sample (finger prick test) and physical examination were performed on sample of 168 participants consented in this study. Pre-validated Malay versions of International Physical Activity 7 (IPAQ-7) and Perceived Stress Scale (PSS) questionnaires were used to assess the level of physical activity and stress levels of the participants. Multinomial logistic regression models were fitted to identify factors associated with prediabetes and diabetes.Results The prevalence of diabetes and prediabetes were 19.6% (95% CI: 14.3, 26.4) and 10.12% (95% CI: 6.4, 15.7) respectively. The median physical activity (interquartile range) in MET-minutes per week for those with diabetes (1071.0 (2120.0)) and prediabetes (1314.0 (1710.0)) was generally lower as compared to non-diabetes. Majority reported moderate stress (57.3%) from PSS system. Abdominal obesity, family history of diabetes and being hypertensive were significant factors associated with diabetes; while older age, bigger waist circumference and self-perceived poor routine diet were factors associated with prediabetes.Conclusions The screening for prediabetes in this population gives the opportunity to implement lifestyle interventions at the earliest possible, which could prevent the development of diabetes. The identification of diabetic individuals provides an opportunity to conduct health promotion and education to ensure good metabolic control and hence reduce the risks of complications.

Hong Kong HK: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 8.330 % in 2017. Hong Kong HK: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 8.330 % from Dec 2017 (Median) to 2017, with 1 observations. Hong Kong HK: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Hong Kong SAR – Table HK.World Bank.WDI: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;